Polivy 30 mg powder for concentrate for solution for infusion.
Sponsors
AbbVie Deutschland GmbH & Co. KG, F. Hoffmann-La Roche AG, Instytut Hematologii I Transfuzjologii, Medical University Of Vienna
Conditions
B-cell Non-Hodgkin's lymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Diffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCLDiffuse large B-cell lymphomas (DLBCLHigh-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiationMantle cell lymphomadiffuse large B-cell lymphoma
Phase 1
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma
RecruitingCTIS2023-505347-38-00
Start: 2022-06-13Target: 59Updated: 2025-11-21
A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients with Diffuse Large B-Cell Lymphoma following First-Line Immunochemotherapy and as Monotherapy or In Combination With Polatuzumab Vedotin in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
CompletedCTIS2023-507498-16-00
Start: 2019-07-02End: 2025-08-06Target: 39Updated: 2025-07-14
Phase 2
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
Not yet recruitingCTIS2024-518275-64-00
Target: 340Updated: 2025-11-24
Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma- A single center phase II trial
CompletedCTIS2024-518704-41-00
Start: 2023-07-12End: 2025-06-17Target: 16Updated: 2024-12-10